Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 3Thoracic Neoplasms 1Squamous Non-small Cell Lung Cancer 1Squamous Non Small Cell Lung Cancer 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Non-small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Lung Diseases 1Carcinoma 1Breast Neoplasms 1

Interventions

Carboplatin 15Pemetrexed 7Paclitaxel 7pembrolizumab 4durvalumab 4osimertinib 3entinostat 3Gemcitabine 3Erlotinib Hydrochloride 3Cisplatin 3selpercatinib 2pralsetinib 2efatutazone 2atezolizumab 2Radiosurgery 2taletrectinib 1sotorasib 1repotrectinib 1patritumab 1necitumumab 1napabucasin 1ficlatuzumab 1exemestane 1cobimetinib 1ceralasertib 1cemiplimab 1camrelizumab 1alectinib 1aflutinib 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Respiratory Tract Neoplasms × necitumumab × Thoracic × Clear all
NCT02941601 2019-09-27

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 2 Withdrawn
Thoracic

Lung Diseases, Lung Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡